HOLT "Global Stock Highlights from the Week - 22 May 2026" Patel

Research evidence excerpt

HOLT "Global Stock Highlights from the Week - 22 May 2026" Patel

Jazz Pharmaceuticals (JAZZ) hits all time high; Shares still trade at a

(7)

discount to history on a host of valuation metrics

JAZZ has seen CFROI decline to ~16% over the past three years due to weaker asset

turns as sales growth slowed when generics to Xyrem launched in the market. Despite

the shares hitting an all-time high this week on strong investor sentiment from the

commercial potential of Ziihera, they trade below their 15-year median across HOLT

valuation metrics, with the market pricing for a much steeper fade in CFROI to ~9%

longer term. Assuming IBES estimates through 2028, current pricing embeds

expectations of no long-term topline growth (click here).

Industrials

Vertiv (VRT) slides despite management disclosing bullish targets; stock

(8)

baking in sharp fade

Vertiv (VRT) shares declined ~15% this week in spite of the company laying out strong

2030 targets including a 20-22% organic sales growth CAGR and a 27% operating

margin. Critical to the debate around high growth AI Industrials like VRT is not just

forming a view around whether they can capitalize on the data center build-out in the

near-to-medium-term, but understanding what’s baked in long-term. Assuming VRT

hits management’s 2030 targets, the stock is priced for sales growth to fade from the

20%+ CAGR to <10% per annum over the balance of a 10-year explicit forecast

window in conjunction with 250bps of margin contraction (click here).

Experian down 6% despite strong FY26 results and further $1bn

(9)

buyback announced; priced for 6% p.a. long-term sales growth

The company’s shares fell 6% despite reporting FY26 adjusted EPS and q/q organic sales

growth marginally ahead of consensus and announcing a further $1bn buyback for

FY27.